50% Hemolysis Rate (HC50) Test: Step-by-Step Experimental Procedure

The 50% hemolysis rate test (HC50 assay) is a widely used in vitro hemocompatibility method that determines the concentration of a test substance required to lyse 50% of red blood cells, providing quantitative insight into the blood-damaging potential of medical devices, biomaterials, and chemical compounds. This article presents a complete technical protocol for the 50% hemolysis rate experiment, covering reagent preparation, blood handling, incubation, spectrophotometric measurement, and result calculation in accordance with recognized standards such as ISO 10993-4, ASTM F756, and GB/T 16886.4.

Technical Overview

The 50% hemolysis rate experiment, also known as the HC50 (50% hemolytic concentration) assay, is a quantitative in vitro test used to evaluate the hemolytic activity of a test material or its extract toward mammalian erythrocytes. Unlike the simple pass/fail hemolysis ratio test, the HC50 method generates a full dose–response curve and identifies the exact concentration at which 50% of red blood cells undergo lysis, making it a sensitive tool for ranking the hemocompatibility of candidate materials.

The test principle is based on the release of hemoglobin when the erythrocyte membrane is damaged by the test substance. After incubation of a standardized red blood cell suspension with serially diluted test samples, intact cells are removed by centrifugation, and the amount of free hemoglobin in the supernatant is quantified by UV–visible spectrophotometry at approximately 540–545 nm. The hemolysis percentage is normalized against a positive control (complete hemolysis) and a negative control (no hemolysis).

The procedure is aligned with internationally recognized hemocompatibility frameworks, including ISO 10993-4 (Biological evaluation of medical devices – Selection of tests for interactions with blood), ASTM F756 (Standard Practice for Analysis of Hemolytic Properties of Materials), and the Chinese national standard GB/T 16886.4. Testing is typically performed by accredited third-party laboratories or in-house biocompatibility facilities under controlled sterile conditions.

Testing Samples

Medical Device Extracts

Extracts prepared from blood-contacting medical devices such as intravenous catheters, stents, blood bags, dialyzer membranes, oxygenators, and infusion sets. Extraction is performed with saline or other polar solvents at 37°C for a defined period, typically following the conditions specified in ISO 10993-12.

Chemical Substances and Surfactants

Raw chemicals, surfactants, disinfectants, and cosmetic ingredients that may accidentally or intentionally contact blood or mucosal tissue. These are tested as aqueous solutions prepared by serial dilution in phosphate-buffered saline (PBS) or 0.9% sodium chloride.

Pharmaceutical and Biologics Candidates

Drug substances, excipients, lipid formulations, and biologics evaluated during preclinical safety screening for their potential to damage erythrocyte membranes upon systemic administration.

Biomaterials and Nanomaterials

Nanoparticles, coatings, hydrogels, and tissue-engineering scaffolds assessed for hemolytic side effects, including both direct-contact and extract-based test configurations.

Testing Items

The core measurable outputs of the 50% hemolysis rate experiment include:

• Hemolysis rate (%) at each test concentration, calculated from absorbance values
• The HC50 value, defined as the sample concentration producing 50% hemolysis relative to the positive control
• The dose–response curve of hemolysis versus sample concentration (log scale)
• Quality control data from positive and negative controls, including absorbance readings and control validity
• Optional supporting parameters such as hemoglobin release concentration and erythrocyte morphology observations

Testing Methods

Step 1: Reagents and Equipment Preparation

Prepare and verify all materials before blood collection to minimize processing delays:

• Phosphate-buffered saline (PBS, pH 7.2–7.4) or sterile 0.9% sodium chloride injection as the dilution medium
• Anticoagulant: heparin, sodium citrate, or Alsever's solution, depending on the protocol
• Positive control: 1% Triton X-100 solution or sterile deionized water, which induces 100% hemolysis
• Negative control: PBS or saline, which should produce negligible hemolysis
• Equipment: refrigerated centrifuge, 37°C water bath or incubator, UV–Vis spectrophotometer or microplate reader set to 540–545 nm, pipettes, centrifuge tubes, and 96-well plates or cuvettes

Step 2: Blood Collection and Erythrocyte Preparation

• Collect fresh blood from healthy New Zealand white rabbits or human donors (with appropriate ethical approval) into anticoagulant-treated tubes.
• Gently invert the tubes to mix without mechanical shearing of the cells.
• Centrifuge the whole blood at approximately 1000–1500 rpm for 5–10 minutes and discard the supernatant plasma and buffy coat.
• Wash the packed erythrocytes 3–5 times with PBS or saline until the wash supernatant is clear.
• Dilute the washed red blood cells with PBS to prepare a uniform suspension, typically 2% (v/v) for microplate formats or 5% (v/v) for tube formats. Gently invert to ensure homogeneity.

Step 3: Preparation of Test Sample Dilution Series

• Dissolve or dilute the test substance in PBS to obtain the highest target concentration.
• Prepare a serial two-fold or geometric dilution series covering the expected hemolytic range, so that the 50% hemolysis point falls within the tested interval.
• For extract-based testing, use the neat extract plus graded dilutions (e.g., 100%, 75%, 50%, 25%, 12.5%).
• Confirm that the test solutions are clear and free of precipitation that could interfere with absorbance readings.

Step 4: Incubation of Erythrocytes with Test Samples

• In each test tube or well, mix equal volumes of test sample dilution and erythrocyte suspension (for example, 0.5 mL + 0.5 mL in tubes, or 100 µL + 100 µL in 96-well plates).
• Set up positive and negative control tubes in parallel, replacing the test sample with Triton X-100 solution and PBS, respectively.
• Incubate all tubes or plates at 37°C for 30 to 60 minutes with gentle inversion every 10–15 minutes to maintain contact between cells and sample.
• Run all samples in triplicate to support statistical evaluation.

Step 5: Centrifugation and Supernatant Collection

• After incubation, optionally place the samples in an ice bath to stop the reaction.
• Centrifuge at 1000–2000 rpm for 5–10 minutes to pellet the intact erythrocytes.
• Carefully transfer the supernatant to clean cuvettes or a fresh microplate without disturbing the cell pellet.

Step 6: Spectrophotometric Measurement

• Measure the absorbance of each supernatant at 540–545 nm, the absorption maximum of oxyhemoglobin; some protocols use 570 nm with drift correction.
• Blank the instrument with PBS or saline.
• Verify control validity: the positive control should show strong absorbance indicating complete hemolysis, while the negative control should remain nearly transparent with minimal absorbance.

Step 7: Calculation of Hemolysis Rate

Calculate the hemolysis percentage for each concentration using the following normalization formula:

Hemolysis rate (%) = (A_sample − A_negative) / (A_positive − A_negative) × 100%, where A_sample is the absorbance of the test sample, A_negative is the absorbance of the PBS/saline negative control, and A_positive is the absorbance of the complete-hemolysis positive control.

Step 8: Determination of the HC50 Value

• Plot the calculated hemolysis rate (%) against the logarithm of the test concentration.
• Fit the dose–response curve using linear regression or a four-parameter logistic model over the linear response range (typically 10–90% hemolysis).
• Read or interpolate the concentration corresponding to 50% hemolysis; this value is reported as the HC50.
• A lower HC50 indicates stronger hemolytic activity, while a higher HC50 indicates better hemocompatibility.

Step 9: Reporting and Interpretation

• Report the HC50 value with units (mg/mL, µg/mL, % v/v, or µg/cm² for extract-based testing), the test conditions, blood source, incubation time, and measurement wavelength.
• For regulatory submissions under ISO 10993-4 or GB/T 16886.4, hemolysis rates below 5% at clinically relevant concentrations are commonly interpreted as non-hemolytic, while results above this threshold warrant further evaluation.
• Document any deviations, hemolysis in the negative control, or sample turbidity that could affect data validity.

Applications

• Biocompatibility evaluation of blood-contacting medical devices such as catheters, cannulae, extracorporeal circuits, heart valves, and vascular grafts as part of ISO 10993-4 test selections
• Comparative screening of surface coatings, antithrombotic treatments, and polymer formulations during medical device R&D
• Safety assessment of surfactants and cleansing ingredients in cosmetic and personal care products
• Preclinical hemolytic toxicity screening of drug candidates, liposomal formulations, and excipients
• Biosafety characterization of nanomaterials, biomaterials, and disinfectant agents intended for clinical or mucosal contact
• Quality control lot-release testing performed by accredited third-party laboratories and manufacturers

FAQ

What does HC50 mean and how is it different from the hemolysis ratio?

HC50 is the concentration of a test substance that causes 50% lysis of erythrocytes, derived from a full dose–response curve. The hemolysis ratio is a single-point measurement, typically at one defined concentration or extract strength, used mainly for pass/fail classification. HC50 provides greater quantitative resolution for comparing materials.

Which blood source is preferred for the test?

Fresh rabbit blood is commonly used in medical device testing per ISO 10993-4 and GB/T 16886.4, while human blood from consenting donors is often used in pharmaceutical and cosmetics testing. Human and rabbit blood may differ slightly in sensitivity, so the source must be stated in the report.

Why is absorbance measured at 540–545 nm?

Oxyhemoglobin released from lysed erythrocytes has an absorption peak near 540–545 nm. Measuring at this wavelength maximizes sensitivity and allows direct normalization against the positive control, assuming hemoglobin release is proportional to the extent of lysis.

What are the acceptance criteria for a valid test?

The positive control must demonstrate near-complete hemolysis with high absorbance, the negative control must remain essentially free of hemolysis, and replicate measurements should show acceptable agreement. Invalid controls require the test to be repeated.

Can the test be adapted for colored or turbid samples?

Yes. For colored or particulate samples, sample blanks without erythrocytes should be measured and subtracted, or alternative readouts such as cyanmethemoglobin quantification or flow cytometry-based erythrocyte counting can be used to correct for optical interference.

How long does the experiment take?

A complete HC50 assay, from blood preparation to data analysis, typically requires one working day. Formal testing by accredited laboratories may take several days to weeks when extraction periods, replicate runs, and full reporting under ISO 10993-4 or GB/T 16886.4 are included.